Search...
/
The Fly Cast
Press play to listen
Smarter market moves start here
Competitive Advantages
Oral Administration Advantage: PHA-022121 offers the significant convenience of an oral pill, differentiating it from many injectable or infused HAE treatments.
Dual Therapeutic Use Potential: The lead product is being developed for both acute, on-demand treatment and long-term prophylactic management of HAE.
Targeted Mechanism of Action: Its focus on bradykinin B2 receptor antagonism addresses a key pathway in HAE, offering a direct and specific therapeutic approach.
Risks
Clinical Trial Outcomes Risk: Failure of deucrictibant or any future product candidates to achieve positive results in ongoing or future clinical trials could significantly harm the company's prospects.
Regulatory Approval Risk: Even with successful clinical trial data, there is no guarantee that regulatory authorities like the FDA or EMA will grant marketing approval for deucrictibant or other product candidates.
Competition Risk: Pharvaris operates in a highly competitive market for hereditary angioedema (HAE) treatments, facing established therapies and other pipeline candidates, which could limit market share.
Today
6:48 AM
Over a week ago
Jun 3, 3:48 PM
May 29, 4:35 PM
May 14, 9:52 AM
May 13, 5:53 AM
May 12, 4:20 PM
May 10, 10:33 AM
Apr 20, 6:54 AM
Apr 15, 3:25 PM
Apr 8, 4:39 PM
Apr 7, 7:38 AM
Apr 6, 8:11 AM
Apr 2, 6:54 AM
Mar 20, 6:53 AM
Mar 11, 6:53 AM
Mar 9, 5:20 AM
Feb 19, 10:38 AM
Dec 4, 7:23 AM
Dec 3, 7:15 PM